ROS1
ENSG00000047936
Target class
Kinase
Chromosome
6
Approved drugs
3
Clinical candidates (approved and in development)
4
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Target name
- ROS1
- Gene name
- ROS proto-oncogene 1, receptor tyrosine kinase
- Gene symbol
- ROS1
- Protein name
- Proto-oncogene tyrosine-protein kinase ROS (EC 2.7.10.1) (Proto-oncogene c-Ros) (Proto-oncogene c-Ros-1) (Receptor tyrosine kinase c-ros oncogene 1) (c-Ros receptor tyrosine kinase)
- MCF3
- ROS
- c-ros-1
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|Fibronectin type III domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 3
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 11.09
- Tissue specificity (Gini)
- 0.939
- Tissue specificity (tau)
- 0.989
- KEGG gene identifiers
- hsa:6098
- Protein interaction confidence
- 0.821643
- Protein interaction partners
- 14
- End position
- 117425942
- Start position
- 117287353
- Chromosome
- 6
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein .
- Vesicles
- Tissue specificity (tau)
- 0.988856
- Expression inequality (Gini)
- 0.938713
Expression in transcripts per million
- Lung
- 11.09
- Cells - Cultured fibroblasts
- 2.96
- Testis
- 1.01
- Brain - Cortex
- 0.83
- Brain - Frontal Cortex (BA9)
- 0.81
Expression in transcripts per million
- Lung11.09
- Cells - Cultured fibroblasts2.96
- Testis1.01
- Brain - Cortex0.83
- Brain - Frontal Cortex (BA9)0.81
- Kidney - Medulla0.2
- Brain - Anterior cingulate cortex (BA24)0.11
- Skin - Not Sun Exposed (Suprapubic)0.09
- Colon - Transverse0.09
- Small Intestine - Terminal Ileum0.07
- Kidney - Cortex0.06
- Pituitary0.06
- Stomach0.04
- Muscle - Skeletal0.03
- Fallopian Tube0.02
- Skin - Sun Exposed (Lower leg)0.02
- Cervix - Endocervix0.02
- Liver0.01
- Nerve - Tibial0.01
- Cells - EBV-transformed lymphocytes0.01
- Pancreas0.01
- Heart - Atrial Appendage0.01
- Prostate0.01
- Minor Salivary Gland0.01
- Adipose - Subcutaneous0.01
And 29 more, listed on the interactive page.
- GO:0001558
- GO:0006468
- GO:0032006
Cellular components
- GO:0016020
- GO:0004713
- GO:0005515
- GO:0019903
Related records
Trials (334)
- -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
- A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
- A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
- A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers
- A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
- A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
- A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
- A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
- A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
- A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Drugs (9)
- Brigatinib
- Crizotinib Proto-oncogene tyrosine-protein kinase ROS inhibitor
- Entrectinib Proto-oncogene tyrosine-protein kinase ROS inhibitor
- Gilteritinib
- Lorlatinib
- Repotrectinib CD74-ROS1 inhibitor
- Taletrectinib Proto-oncogene tyrosine-protein kinase ROS inhibitor
- Taletrectinib adipate Proto-oncogene tyrosine-protein kinase ROS inhibitor
- Zidesamtinib